Condition: Transthyretin-Mediated Amyloidosis · ATTR Amyloidosis · Sponsor: Alnylam Pharmaceuticals
The purpose of this study is to: * Describe epidemiological and clinical characteristics, natural history and real-world clinical management of ATTR amyloidosis patients * Characterize the safety and effectiveness of patisiran and vutrisiran as part of routine clinical practice in the real-world clinical setting * Describe disease emergence/progression in pre-symptomatic carriers of a known disease-causing transthyretin (TTR) variant
This description comes directly from the study's public registry record.
Alnylam Clinical Trial Information Line · 1-877-ALNYLAM · clinicaltrials@alnylam.com
Alnylam Clinical Trial Information Line · 1-877-256-9526 · clinicaltrials@alnylam.com
Always discuss trial participation with your own doctor first.
| Clinical Trial Site | La Jolla, California, United States | Recruiting |
| Clinical Trial Site | Los Angeles, California, United States | Recruiting |
| Clinical Trial Site | Jacksonville, Florida, United States | Recruiting |
| Clinical Trial Site | Iowa City, Iowa, United States | Recruiting |
| Clinical Trial Site | Kansas City, Kansas, United States | Recruiting |
| Clinical Trial Site | Baltimore, Maryland, United States | Recruiting |
| Clinical Trial Site | Boston, Massachusetts, United States | Completed |
| Clinical Trial Site | New York, New York, United States | Recruiting |
| Clinical Trial Site | Durham, North Carolina, United States | Recruiting |
| Clinical Trial Site | Columbus, Ohio, United States | Recruiting |
| Clinical Trial Site | Philadelphia, Pennsylvania, United States | Recruiting |
| Clinical Trial Site | Austin, Texas, United States | Recruiting |
+ 28 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT04561518